ClinicalTrials.gg
TerminatedNCT01845025Updated Mar 21, 2017Results posted

Study of Safety of Foradil in Patients With Persistent Asthma

A Phase 4 interventional study of Formoterol 12 mcg and Fluticasone propionate 100 mcg in Persistent Asthma, sponsored by Novartis Pharmaceuticals. Terminated at 27 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was a commercial reason and not due to any change in benefit-risk.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
827
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.

Enrollment
15th of 85
827 · median 100
Started
2013
with 2 others
Phase 4
11 of 86
none open now
Registered
62nd of 86
by date

Among the 86 studies testing formoterol in Asthma, this one is the 15th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 in phase 4, and was the 62nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing formoterol in Asthma, or all of them as a file.
02

Study summary

The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone propionate alone.

Read the detailed description

This was a 26 week, double blind, randomized, active-controlled safety study of Foradil in free combination with inhaled corticosteroid versus an inhaled corticosteroid alone in adults and adolescent patients with persistent asthma. The primary objective of the study was to demonstrate that the addition of formoterol fumarate to fluticasone propionate is non-inferior to fluticasone propionate alone in terms of the risk of composite serious asthma related events (asthma-related hospitalization, asthma-related intubation, and asthma-related death). The individual components of the composite primary endpoint (i.e., asthma-related hospitalization, asthma-related intubation and asthma-related death) will be assessed as a secondary safety endpoints.

The efficacy assessment is the secondary objective.

03

Conditions studied

  • Persistent Asthma

Browse trials for

Keywords

  • Asthma
  • formoterol fumarate
  • Foradil
  • inhaled corticosteroid
  • fluticasone propionate
  • safety
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Written , and assent if applicable, must be obtained before any assessment is performed.
  2. Male or female patients 12 years of age and older
  3. Confirmed diagnosis of persistent asthma, as defined by national and international asthma guidelines (e.g., GINA; NIH; etc.) for at least 1 year prior to study enrollment.
  4. PEF≥50% of predicted normal value.
  5. Current and appropriate use of one of the treatments listed in the protocol for asthma.
  6. Recent asthma exacerbation between 30 days and 12 months prior to randomization that either:

    • required treatment with systemic (tablets, suspension, or injection) or
    • required hospitalization (defined as an inpatient stay or >24-hour stay in an observation area in an emergency room or other equivalent facility)

Key Exclusion Criteria:

  1. History of life-threatening asthma episode that required intubation and/or was associated with hypercapnia requiring non-invasive ventilatory support.
  2. Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other respiratory abnormalities other than asthma.
  3. Current evidence of, or past physician assessment of, chronic bronchitis, emphysema, or .
  4. History of smoking ≥ 10 pack years.
  5. Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine.
  6. Suspected or documented bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved at randomization.
  7. Worsening/Unstable asthma within 7 days prior to randomization.
  8. Any asthma exacerbation requiring systemic corticosteroids within 30 days of randomization or more than 4 separate exacerbations in the 12 months preceding randomization.
  9. Two or more hospitalizations for greater than 24 hours duration for treatment of asthma in the 12 months preceding randomization.
  10. History of to any beta2-agonist, sympathomimetic drug, inhaled corticosteroids, or systemic corticosteroid therapy or any component of the possible study treatments in this trial, including severe milk protein hypersensitivity.
  11. Use of anti-IgE (e.g., omalizumab) or any other monoclonal antibody, in the 6 months prior to randomization.
  12. Use of (Beta) β-blockers within 1 day prior to first dose of study medication.
  13. Use of ICS, LABA, ICS+LABA, LTRAs, leukotriene modifiers, anticholinergics, or theophylline must be discontinued prior to the first dose of treatment.
  14. Use of a potent inhibitor within 4 weeks of randomization (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
827 participants (actual)

Study arms

  • Experimental
    FOM 12 mcg + FP

    Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation

    Drug: Formoterol 12 mcg · Drug: Fluticasone propionate 100 mcg · Drug: Fluticasone propionate 250 mcg · Drug: Fluticasone propionate 500 mcg

  • Active comparator
    fluticasone propionate (FP)

    fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation

    Drug: Fluticasone propionate 100 mcg · Drug: Fluticasone propionate 250 mcg · Drug: Fluticasone propionate 500 mcg · Drug: Placebo

Interventions

  • Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler

    Also known as: FOR258

  • Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler

  • Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler

  • Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler

  • DrugPlacebo

    Placebo to match formoterol one inhalation twice daily via dry powder inhaler

06

What researchers measure

Primary outcomes

  1. Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks

    The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 \* n patients with any events / total N patients in treatment group.

    Time frame: 26 weeks

Secondary outcomes

  1. Number of Asthma Exacerbations at 26 Weeks

    Number of asthma exacerbations events

    Time frame: 26 weeks

  2. Percentage of Days of School/Work Missed at 26 Weeks

    The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.

    Time frame: 26 weeks

  3. Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks

    The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.

    Time frame: 26 weeks

  4. Percentage of Days With Nighttime Awakenings at 26 Weeks

    Percentage of days with nighttime awakenings during the treatment period (26 weeks)

    Time frame: 26 weeks

  5. Percentage of Days With no Rescue Medication Use at 26 Weeks

    Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.

    Time frame: 26 weeks

  6. Percentage of Days With no Symptoms at 26 Weeks

    Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.

    Time frame: 26 weeks

  7. Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26

    Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.

    Time frame: baseline and 26 weeks

  8. Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)

    Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (\< 24 hours); Hospital admission or Emergency department visit (\> 24 hours).

    Time frame: Week 4, Week 12, and Week 26

07

Results

Posted Mar 21, 2017

Participant flow

Following the decision to stop further enrollment into the study, 1121 patients had been screened, of whom 825 were randomized. Of the 820 patients randomized and treated and part of Intent To Treat (ITT analysis) 5 patients were randomized but were excluded from the ITT analyses as they did not take study medication.

Participant flow — Overall Study
MilestoneFOM 12 mcg + FPFluticasone Propionate (FP)
Started411409
Completed326332
Not completed8577
Withdrew: Adverse event63
Withdrew: Unsatisfactory therapeutic effect42
Withdrew: Withdrawal by subject4844
Withdrew: Lost to follow-up1313
Withdrew: Administrative problems88
Withdrew: Death20
Withdrew: Protocol deviation36
Withdrew: Missing11

Outcome measures

PrimaryNumber of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks

The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 \* n patients with any events / total N patients in treatment group.

Time frame:
26 weeks
Reported as:
Number · number of occurences
Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks
number of occurencesFOM 12 mcg + FPFluticasone Propionate (FP)
Composite event33
Asthma-related death00
Asthma-related intubation00
Asthma-related hospitalization33
SecondaryNumber of Asthma Exacerbations at 26 Weeks

Number of asthma exacerbations events

Time frame:
26 weeks
Reported as:
Mean · events
Number of Asthma Exacerbations at 26 Weeks
eventsFOM 12 mcg + FPFluticasone Propionate (FP)
Number of Asthma Exacerbations at 26 Weeks1.3 ± 0.621.2 ± 0.51
SecondaryPercentage of Days of School/Work Missed at 26 Weeks

The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.

Time frame:
26 weeks
Reported as:
Mean · percentage of days
Percentage of Days of School/Work Missed at 26 Weeks
percentage of daysFOM 12 mcg + FPFluticasone Propionate (FP)
Percentage of Days of School/Work Missed at 26 Weeks0.97 ± 4.5580.56 ± 1.641
SecondaryPercentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks

The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.

Time frame:
26 weeks
Reported as:
Mean · percentage of days
Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks
percentage of daysFOM 12 mcg + FPFluticasone Propionate (FP)
Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks4.73 ± 12.7744.75 ± 12.705
SecondaryPercentage of Days With Nighttime Awakenings at 26 Weeks

Percentage of days with nighttime awakenings during the treatment period (26 weeks)

Time frame:
26 weeks
Reported as:
Mean · percentage of days
Percentage of Days With Nighttime Awakenings at 26 Weeks
percentage of daysFOM 12 mcg + FPFluticasone Propionate (FP)
Percentage of Days With Nighttime Awakenings at 26 Weeks4.55 ± 9.5774.20 ± 8.956
SecondaryPercentage of Days With no Rescue Medication Use at 26 Weeks

Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.

Time frame:
26 weeks
Reported as:
Mean · percentage of days
Percentage of Days With no Rescue Medication Use at 26 Weeks
percentage of daysFOM 12 mcg + FPFluticasone Propionate (FP)
Percentage of Days With no Rescue Medication Use at 26 Weeks76.97 ± 27.25573.29 ± 30.640
SecondaryPercentage of Days With no Symptoms at 26 Weeks

Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.

Time frame:
26 weeks
Reported as:
Mean · percentage of days
Percentage of Days With no Symptoms at 26 Weeks
percentage of daysFOM 12 mcg + FPFluticasone Propionate (FP)
Percentage of Days With no Symptoms at 26 Weeks79.47 ± 25.50177.64 ± 28.394
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26

Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.

Time frame:
baseline and 26 weeks
Reported as:
Mean · total score on a scale
Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26
total score on a scaleFOM 12 mcg + FPFluticasone Propionate (FP)
Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26-0.65 ± 1.224-0.59 ± 1.094
SecondaryUnplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)

Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (\< 24 hours); Hospital admission or Emergency department visit (\> 24 hours).

Time frame:
Week 4, Week 12, and Week 26
Reported as:
Number · unplanned visits
Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)
unplanned visitsFOM 12 mcg + FPFluticasone Propionate (FP)
Telephone contact with study MD: V31918
Telephone contact with other MD or HCP: V359
unplanned visit to study MD;include home:V3713
unplanned visit to other MD or HCP incl.home:V359
Emergency or hospital visit (< 24 hours):V334
Hospital admission or Emergency visit (>24hrs):V311
Telephone contact with study MD: V42517
Telephone contact with other MD or HCP: V457
unplanned visit to study MD;include home:V41015
unplanned visit to other MD or HCP incl.home:V41516
Emergency or hospital visit (< 24 hours):V434
Hospital admission or Emergency visit (>24hrs):V402
Telephone contact with study MD: V5149
Telephone contact with other MD or HCP: V582
unplanned visit to study MD;include home:V569
unplanned visit to other MD or HCP incl.home:V5107
Emergency or hospital visit (< 24 hours):V546
Hospital admission or Emergency visit (>24hrs):V520

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FOM 12 mcg + FP—10/411 (2.4%)5/411 (1.2%)
Fluticasone Propionate (FP)—9/409 (2.2%)9/409 (2.2%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventFOM 12 mcg + FPFluticasone Propionate (FP)
AsthmaRespiratory, thoracic and mediastinal disorders2/4112/409
OsteoarthritisMusculoskeletal and connective tissue disorders2/4110/409
Upper gastrointestinal haemorrhageGastrointestinal disorders0/4111/409
CellulitisInfections and infestations0/4111/409
PneumoniaInfections and infestations1/4111/409
TracheobronchitisInfections and infestations0/4111/409
Alcohol poisoningInjury, poisoning and procedural complications0/4111/409
OverdoseInjury, poisoning and procedural complications0/4111/409
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4111/409
Cerebrovascular accidentNervous system disorders0/4111/409
Most frequent other events
Most frequent other events
EventFOM 12 mcg + FPFluticasone Propionate (FP)
AsthmaRespiratory, thoracic and mediastinal disorders5/4119/409

Baseline characteristics

Age, Continuous
Age, Continuous(years)FOM 12 mcg + FPFluticasone Propionate (FP)Total
Mean44.7 ± 16.6745.6 ± 17.0245.2 ± 16.84
Sex: Female, Male
Sex: Female, Male(Participants)FOM 12 mcg + FPFluticasone Propionate (FP)Total
Female284272556
Male127137264
08

Study locations

27 sites
  • Novartis Investigative Site
    Avondale, Arizona 85323, United States
  • Novartis Investigative Site
    North Hollywood, California 91606, United States
  • Novartis Investigative Site
    Bradenton, Florida 34209, United States
  • Novartis Investigative Site
    Miami, Florida 33126, United States
  • Novartis Investigative Site
    Miami, Florida 33134, United States
  • Novartis Investigative Site
    Conyers, Georgia 30012, United States
  • Novartis Investigative Site
    Stone Mountain, Georgia 30083, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40214, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40220, United States
  • Novartis Investigative Site
    Covington, Louisiana 70433, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21287, United States
  • Novartis Investigative Site
    Gaithersburg, Maryland 20878, United States
  • Novartis Investigative Site
    Picayune, Mississippi 39466, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63117, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63128, United States
  • Novartis Investigative Site
    North Massapequa, New York 11758, United States
  • Novartis Investigative Site
    Elizabeth City, North Carolina 27909, United States
  • Novartis Investigative Site
    Winston Salem, North Carolina 27103, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44106-5000, United States
  • Novartis Investigative Site
    Oaks, Pennsylvania 19456, United States
  • Novartis Investigative Site
    East Greenwich, Rhode Island 02818, United States
  • Novartis Investigative Site
    Mount Pleasant, South Carolina 29464, United States
  • Novartis Investigative Site
    Memphis, Tennessee 38118, United States
  • Novartis Investigative Site
    Dallas, Texas 75235, United States
  • Novartis Investigative Site
    Saint George, Utah 84790, United States
  • Novartis Investigative Site
    Mequon, Wisconsin 53092, United States
  • Novartis Investigative Site
    Milwaukee, Wisconsin 53172, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2013
First posted
May 3, 2013
Start
May 2013
Primary completionActual
May 2016
CompletionActual
May 2016
Results first posted
Mar 21, 2017
Last update
Mar 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01845025
Responsible party
Sponsor
First posted
May 3, 2013
Start date
May 2013
Primary completion
May 2016
Completion
May 2016
Results posted
Mar 21, 2017
Last update
Mar 21, 2017

Study contacts

Chrsitopher Compton
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion